| P2093 | author name string | Sagar Lonial | |
| P2860 | cites work | Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma | Q34596711 |
| | A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study | Q39844074 |
| | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. | Q42914716 |
| | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. | Q42921022 |
| | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m | Q60203634 |
| | Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial | Q80776203 |
| | Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib | Q83930160 |
| P433 | issue | 2 | |
| P304 | page(s) | 73-74 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Is subcutaneous bortezomib ready for prime time? | |
| P478 | volume | 6 | |